About Organogenesis
Organogenesis is a publicly listed company based in Canton (United States) founded in 1985, and was acquired by Avista Capital Partners in August 2018. Regenerative therapies for wound care are developed and commercialized. Organogenesis has raised $30 million across 4 funding rounds from investors including Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners. The company has 869 employees. Organogenesis has completed 1 acquisition, including Nutech Medical. Its chief executive, as recorded, is Gary S Gillheeney. Its website organogenesis.com draws about 15 thousand monthly visits. Organogenesis offers products and services including PuraPlyAM, NuShield, Apligraf, and Affinity. Its focus areas include Life Sciences, Cell Therapy, Diversified and Regenerative Medicine. Its legal entity is Organogenesis Holdings Inc. Its competitors include Tenaya Therapeutics, Athira Pharma and Ensoma; 3 of its 3 listed competitors have raised funding.
Company details
Organogenesis, an MIT spin-off, develops regenerative therapies for wound care. It has four approved products on the market. Apligraf is a living cell-based human skin substitute that is indicated for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a human fibroblast-derived dermal substitute for diabetic foot ulcers.PuraPly is a collagen plus polyhexanide antimicrobial wound filling matrix. Additionally, Organogenesis also received FDA clearance for Gintuit, a scaffold product made of allogeneic cultured keratinocytes and fibroblasts, indicated for mucogingival conditions in adults.
- Headquarters Canton, United States
- Employees 869
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website organogenesis.com
- Social LinkedIn Facebook Instagram
- Acquired by Avista Capital Partners (Aug 2018)
- Legal Name Organogenesis Holdings Inc.
- Annual Revenue$564.17 M (USD)17.04as on Dec 31, 2025
- Net Profit$37.03 M (USD)4201.05as on Dec 31, 2025
- EBITDA$83.32 M (USD)76.88as on Dec 31, 2025
- Total Equity Funding$30M (USD)
in 4 rounds
- Latest Funding Round$130M (USD), Post-IPO
Nov 2024
- InvestorsEastward Capital Partners
& 2 more
- Employee Count869
- Investments & Acquisitions
- Acquired byAvista Capital Partners
(Aug 2018)
Products & Services of Organogenesis
Organogenesis offers a comprehensive portfolio of products and services, including PuraPlyAM, NuShield, Apligraf, and Affinity.
Regenerative matrix for advanced wound healing treatments.
Biological graft for tissue repair in medical procedures.
Engineered skin substitute for chronic wound management.
Matrix for surgical and sports medicine applications.
Funding Insights of Organogenesis
Organogenesis has successfully raised a total of $30M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 4
- Last Round Post-IPO — $130M
- First Round $7.4M
(Jan 2009)
- Investors Count 2
All 4 funding rounds of Organogenesis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $130M | Post-IPO | – | – | – |
| May 2017 | $20M | Debt – Conventional | – | – | |
| Apr 2016 | $30M | Series C | – | – | – |
| Jan 2009 | $7.4M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Organogenesis
Organogenesis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm that does debt investment in the US | eastwardcp.com | Newton, United States | ||
Life sciences innovation is supported through funding and programs. | masslifesciences.com | Waltham, United States | ||
Private equity investments are focused on the United States market. | avistacap.com | New York, United States |
Investor details for Organogenesis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Organogenesis
194 people are tracked at Organogenesis (62 in leadership, 132 in team); the tracked headcount is 869.
| Name | Role | Group |
|---|---|---|
Gary S Gillheeney | CEO | Leadership |
Mark Hardmon | Senior Director Program Management Office | Leadership |
Megan Watson | Director Of Talent Acquisition | Leadership |
Patrick Bilbo | COO | Leadership |
Scott M. | Director, Commercial Operations & Analytics | Leadership |
Travis Veraghen | Senior Director Sales - Surgical | Leadership |
Ed Jackson | Area Director Of Sales | Leadership |
Mike Johnson | Area Director Of Sales | Leadership |
Scott Constantine | Vice President Clinical Operations | Leadership |
Antonio S. Montecalvo | VP, Health Policy | Leadership |
Mark Collins | VP, Business Relations & Corporate Accounts | Leadership |
Houda Samaha | Director Of Human Resources | Leadership |
Robert Cavorsi | VP, Strategy | Leadership |
Jamie Garay-Lehmann | VP, Manufacturing Operations | Leadership |
Richard J. Dupré | Regional Sales Director | Leadership |
Kurt Matheson | VP, Marketing | Leadership |
Dave Francisco | Chief Financial Officer | Leadership |
David C. Francisco | CFO | Leadership |
Shannon Banks | Vp, Manufacturing Operations | Leadership |
Charles Young | Senior Director Of Manufacturing | Leadership |
174 more people are available in the full profile.
Complete people profiles for Organogenesis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Organogenesis
Organogenesis is a publicly listed company on the NASDAQ with ticker symbol ORGO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Nov 2018
- Listed onNASDAQ: ORGO
- Listed entityOrganogenesis Holdings Inc.
- Exchange sectorHealth technology
- ISINUS68621F1021
- Share price$1.21 (-1.63% on the day) · 2026-10-13
- Market capitalisation$155.7M
- EPS (diluted, trailing year)$-0.83
- Volume (last session)706,933
Financials of Organogenesis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $564.2M | $37.0M | $83.3M |
| 2024 | $482.0M | $861,000 | $47.1M |
| 2023 | $433.1M | $5.0M | $39.8M |
| 2022 | $450.9M | $15.5M | $46.8M |
| 2021 | $467.4M | $94.2M | $93.6M |
Detailed financial statements for Organogenesis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Organogenesis
Organogenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nutech Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biologic and medical device company focusing on spinal and orthopedic surgical products | nutechmedical.com | Birmingham, United States | 1994 | Mar 2017 | •••• |
Complete acquisition details for Organogenesis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Organogenesis
6 dated milestones of Organogenesis across 39 years, from founding to its latest funding, stage changes and deals.
- Founded Organogenesis is founded.
- Funding First funding round of $7.4M.
- Acquisition Acquires Nutech Medical.
- Exit Acquired by Avista Capital Partners.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $130.0M.
Competitors of Organogenesis
Organogenesis has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Athira Pharma and Ensoma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| athira.com | 2011 | Seattle, United States | $121.04M | 62 | Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool |
Detailed competitors of Organogenesis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Organogenesis
The website of Organogenesis (organogenesis.com) receives about 14.8K visits a month.
- Monthly visits14.8K
▼ 30.4% vs previous month
Websites whose visitors overlap most with Organogenesis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
revmedconnect.com | revmedconnect.com | 100% | #771,336 | – | |
| woundreference.com | 86% | 15.7K | #1,476,557 | View details | |
juven.com | juven.com | 56% | #1,508,945 | – | |
lifelinktissuebank.org | lifelinktissuebank.org | 27% | #3,855,523 | – | |
diversityfirstjobs.com | diversityfirstjobs.com | 26% | #15,228,265 | – |
Top companies in Cell Therapy
3 companies that operate in the same segment as Organogenesis (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Organogenesis
Complete news archive for Organogenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organogenesis
Organogenesis was founded in 1985 and raised its 1st funding round 24 years after it was founded.
Organogenesis is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Gary S Gillheeney is the CEO of Organogenesis, as recorded in our data.
Organogenesis is a funded company, having raised a total of $30M across 4 funding rounds to date. The company's 1st funding round was a Grant of $7.4M, raised on Jan 2009.
Organogenesis has 869 employees.
Annual revenue of Organogenesis is $564.17M as on Dec 31, 2025.
Organogenesis, an MIT spin-off, develops regenerative therapies for wound care. It has four approved products on the market. Apligraf is a living cell-based human skin substitute that is indicated for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a human fibroblast-derived dermal substitute for diabetic foot ulcers.PuraPly is a collagen plus polyhexanide antimicrobial wound filling matrix. Additionally, Organogenesis also received FDA clearance for Gintuit, a scaffold product made of allogeneic cultured keratinocytes and fibroblasts, indicated for mucogingival conditions in adults.
Organogenesis's top competitors include Tenaya Therapeutics, Athira Pharma and Ensoma.
Organogenesis offers PuraPlyAM, NuShield, Apligraf, and Affinity.
Yes, Organogenesis is publicly traded on NASDAQ under the ticker symbol ORGO.
Organogenesis has made 1 acquisition, including Nutech Medical.
Organogenesis has 3 investors. Key investors include Eastward Capital Partners, Massachusetts Life Sciences Center, and Avista Capital Partners.